Literature DB >> 21281278

Carotid intima media thickness is associated with plasma lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in patients with type 2 diabetes.

Alexander Constantinides1, L Joost van Pelt, Jeroen J J van Leeuwen, Rindert de Vries, René A Tio, Iwan C C van der Horst, Wim J Sluiter, Robin P F Dullaart.   

Abstract

BACKGROUND: A recent meta-analysis showed that both plasma lipoprotein-associated phospholipase A(2) (Lp-PLA(2) ) mass and activity independently predict cardiovascular events. Notably, Lp-PLA(2) activity but not mass was found to be a determinant of cardiovascular outcome in type 2 diabetes mellitus. We questioned whether relationships of carotid intima media thickness (IMT), a measure of subclinical atherosclerosis, with Lp-PLA(2) mass differ between diabetic and nondiabetic subjects.
MATERIALS AND METHODS: Relationships of IMT with plasma Lp-PLA(2) mass (turbidimetric immunoassay) were compared in 74 patients with type 2 diabetes and in 64 nondiabetic subjects.
RESULTS: IMT was increased (P=0·016), but plasma Lp-PLA(2) mass was decreased in patients with diabetes compared to nondiabetic subjects (277±66 vs. 327±62μgL(-1) , P<0·001). In nondiabetic subjects, IMT was correlated positively with Lp-PLA(2) (r=0·325, P<0·009); multiple linear regression analysis confirmed an independent association of IMT with Lp-PLA(2) (ß=0·192, P=0·048). In contrast, IMT was unrelated to Lp-PLA(2) in patients with diabetes (r=0·021, P=0·86), and the relationship of IMT with Lp-PLA(2) was different in diabetic and control subjects (P<0·001). The relationship of Lp-PLA(2) with the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio also differed between diabetic and nondiabetic subjects (P<0·001).
CONCLUSIONS: Plasma Lp-PLA(2) may relate to early stages of atherosclerosis development. In diabetes mellitus, in contrast, the association of IMT with plasma Lp-PLA(2) mass is abolished, which could be partly ascribed to redistribution of Lp-PLA(2) mass from apolipoprotein B-containing lipoproteins towards HDL. These findings raise questions about the usefulness of plasma Lp-PLA(2) mass measurement as a marker of subclinical atherosclerosis in type 2 diabetes mellitus.
© 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21281278     DOI: 10.1111/j.1365-2362.2011.02471.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  3 in total

1.  Lipoprotein-associated phospholipase A2 activity in obese adolescents with and without type 2 diabetes.

Authors:  Julia Seyfarth; Thomas Reinehr; Annika Hoyer; Christina Reinauer; Christina Bächle; Beate Karges; Ertan Mayatepek; Michael Roden; Sabine E Hofer; Susanna Wiegand; Joachim Woelfle; Wieland Kiess; Joachim Rosenbauer; Reinhard W Holl; Thomas Meissner
Journal:  J Inherit Metab Dis       Date:  2017-10-13       Impact factor: 4.982

2.  Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A2 and secretory phospholipase A2 in patients with newly diagnosed type 2 diabetes.

Authors:  Xiu-Hong Lin; Ming-Tong Xu; Jv-Ying Tang; Li-Fang Mai; Xiao-Yi Wang; Meng Ren; Li Yan
Journal:  Lipids Health Dis       Date:  2016-11-23       Impact factor: 3.876

3.  Lipoprotein-associated phospholipase A(2) mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: the Strong Heart Study.

Authors:  Jorge R Kizer; Jason G Umans; Jianhui Zhu; Richard B Devereux; Robert L Wolfert; Elisa T Lee; Barbara V Howard
Journal:  Diabetes Care       Date:  2012-02-14       Impact factor: 19.112

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.